JP2018524373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524373A5 JP2018524373A5 JP2018501976A JP2018501976A JP2018524373A5 JP 2018524373 A5 JP2018524373 A5 JP 2018524373A5 JP 2018501976 A JP2018501976 A JP 2018501976A JP 2018501976 A JP2018501976 A JP 2018501976A JP 2018524373 A5 JP2018524373 A5 JP 2018524373A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- construct
- binding
- binding polypeptide
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 344
- 102000036639 antigens Human genes 0.000 claims description 344
- 108091007433 antigens Proteins 0.000 claims description 344
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 157
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 150
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 239000000203 mixture Substances 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 78
- 229940079593 drug Drugs 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 59
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 58
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 32
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 32
- 238000012986 modification Methods 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000000099 in vitro assay Methods 0.000 claims description 13
- 229960003008 blinatumomab Drugs 0.000 claims description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 10
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 10
- 102100024153 Cadherin-15 Human genes 0.000 claims description 9
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims description 9
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 7
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 7
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 5
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 102100031013 Transgelin Human genes 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009490 IgG Receptors Human genes 0.000 claims description 4
- 108010073807 IgG Receptors Proteins 0.000 claims description 4
- 102000029749 Microtubule Human genes 0.000 claims description 4
- 108091022875 Microtubule Proteins 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 210000004688 microtubule Anatomy 0.000 claims description 4
- 229950010127 teplizumab Drugs 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 229940127174 UCHT1 Drugs 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 101000642536 Apis mellifera Venom serine protease 34 Proteins 0.000 claims description 2
- 208000037914 B-cell disorder Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 241000282577 Pan troglodytes Species 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 229940050282 inebilizumab-cdon Drugs 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 35
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000003053 toxin Substances 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- 108010080422 CD39 antigen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193056P | 2015-07-15 | 2015-07-15 | |
| US62/193,056 | 2015-07-15 | ||
| US201562193569P | 2015-07-16 | 2015-07-16 | |
| US62/193,569 | 2015-07-16 | ||
| PCT/CA2016/050839 WO2017008169A1 (en) | 2015-07-15 | 2016-07-15 | Drug-conjugated bi-specific antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524373A JP2018524373A (ja) | 2018-08-30 |
| JP2018524373A5 true JP2018524373A5 (enExample) | 2019-08-22 |
Family
ID=57756601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501976A Pending JP2018524373A (ja) | 2015-07-15 | 2016-07-15 | 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11147886B2 (enExample) |
| EP (1) | EP3322735A4 (enExample) |
| JP (1) | JP2018524373A (enExample) |
| CN (1) | CN108137706A (enExample) |
| CA (1) | CA2991799A1 (enExample) |
| WO (1) | WO2017008169A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3283524T3 (pl) * | 2015-04-17 | 2023-06-12 | Amgen Research (Munich) Gmbh | Konstrukty biswoistego przeciwciała dla cdh3 i cd3 |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| SG11201906319XA (en) * | 2017-01-20 | 2019-08-27 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CA3064714A1 (en) * | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and a tumor-associated antigen |
| EP3685166A2 (en) * | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| MX2020012217A (es) | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| SI3844267T1 (sl) | 2018-08-31 | 2025-10-30 | Novartis Ag | Postopki izdelave celic, ki izražajo receptorje himernega antigena |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) * | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| US20220023430A1 (en) * | 2018-11-13 | 2022-01-27 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3959237A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| CN110423723A (zh) * | 2019-07-18 | 2019-11-08 | 南方医科大学南方医院 | 一种外周血b细胞系的构建方法及其应用 |
| BR112022004712A2 (pt) * | 2019-09-16 | 2022-06-14 | Gt Biopharma Inc | Compostos e métodos de imunoterapia |
| WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| CN115916818A (zh) * | 2019-12-11 | 2023-04-04 | 库利南肿瘤股份有限公司 | 抗cd19抗体和多特异性结合蛋白 |
| CN114829408B (zh) * | 2019-12-20 | 2024-01-26 | 山东博安生物技术股份有限公司 | 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂 |
| IL295878A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
| CN115279412A (zh) * | 2020-02-27 | 2022-11-01 | 凡恩世制药公司 | 偶联脂肪酸分子的抗体及其用途 |
| JP2023516008A (ja) | 2020-02-27 | 2023-04-17 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN111840571B (zh) * | 2020-08-03 | 2022-09-20 | 杭州皓阳生物技术有限公司 | 一种抗体药物偶联物及其用途 |
| US11197910B1 (en) | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| WO2022040586A2 (en) | 2020-08-21 | 2022-02-24 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| EP4247430A4 (en) * | 2020-11-20 | 2024-12-11 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
| US20240034806A1 (en) * | 2020-12-09 | 2024-02-01 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens |
| JP2024506022A (ja) * | 2021-02-08 | 2024-02-08 | シンアフィックス ビー．ブイ． | 多機能性抗体 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2022199555A1 (en) * | 2021-03-23 | 2022-09-29 | Guangzhou Lintonpharm Co., Ltd. | A multispecific antigen binding protein binding to cd3 and the use thereof |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| CN117616137A (zh) * | 2021-05-11 | 2024-02-27 | 佳努克斯治疗公司 | 靶向egfr和cd3的抗体及其用途 |
| AR125758A1 (es) | 2021-05-12 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| US20260007763A1 (en) * | 2022-02-11 | 2026-01-08 | Shenzhen Enduring Biotech, Ltd. | Pegylated antibody hydroxyl-bearing drug conjugate |
| JP2026519263A (ja) | 2022-10-26 | 2026-06-15 | ノバルティス アーゲー | レンチウイルス製剤 |
| EP4653017A1 (en) | 2023-01-18 | 2025-11-26 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| EP4680648A1 (en) * | 2023-03-17 | 2026-01-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-her3 and anti-met antibodies and uses thereof |
| WO2024193682A1 (en) * | 2023-03-23 | 2024-09-26 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-tpbg/met antibodies and uses thereof |
| AU2024375250A1 (en) * | 2023-11-10 | 2026-06-11 | Ligachem Biosciences Inc. | Antibody-drug conjugate comprising bispecific antibody specifically binding to cd20 and cd22 and uses thereof |
| WO2025148868A1 (zh) | 2024-01-08 | 2025-07-17 | 泰励生物科技（上海）有限公司 | 一种抗体偶联药物及其用途 |
| CN120285216A (zh) * | 2024-01-11 | 2025-07-11 | 成都百利多特生物药业有限责任公司 | 澳瑞他汀类药物的配体-药物偶联物及其制备和应用 |
| AU2025206506A1 (en) * | 2024-01-11 | 2026-07-23 | Systimmune, Inc. | Antibody-auristatin drug conjugate and pharmaceutical use thereof |
| WO2025223455A1 (en) | 2024-04-24 | 2025-10-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ptk7/b7h3 antibodies and uses thereof |
| CN119431525B (zh) * | 2024-10-08 | 2025-04-11 | 北京溯本源和生物科技有限公司 | 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| US20050142133A1 (en) * | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| CA2628253A1 (en) | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP2799449A1 (en) | 2006-05-25 | 2014-11-05 | Bayer Intellectual Property GmbH | Dimeric molecular complexes |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| AU2007353412A1 (en) | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| CA2729403A1 (en) * | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| AU2010242338B2 (en) * | 2009-05-01 | 2013-12-19 | Perseus Proteomics Inc. | Anti-cadherin antibody |
| NZ598732A (en) | 2009-10-27 | 2014-09-26 | Amgen Res Munich Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody |
| EP2496598B1 (en) | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN103533943B (zh) | 2010-11-10 | 2018-02-13 | 安进研发（慕尼黑）股份有限公司 | 由cd3特异性结合结构域导致的不良作用的预防 |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| WO2012143524A2 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| ES2806142T3 (es) | 2011-04-28 | 2021-02-16 | Amgen Res Munich Gmbh | Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos |
| WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JP6351572B2 (ja) | 2012-05-10 | 2018-07-04 | ザイムワークス，インコーポレイテッド | Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物 |
| EP2847224A4 (en) | 2012-05-10 | 2016-04-27 | Zymeworks Inc | SINGLE ARM MONOVALENT ANTIBODY CONSTRUCTS AND USES THEREOF |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| IN2015DN01115A (enExample) | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US9382329B2 (en) * | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| KR102391731B1 (ko) * | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10239951B2 (en) | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| BR112016000666A2 (pt) * | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligação de antígeno cd3 e cd19 biespecíficos |
| CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| LT3074424T (lt) | 2013-11-27 | 2025-05-26 | Zymeworks Bc Inc. | Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2 |
| US20160326249A1 (en) | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| MX2016017393A (es) * | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
-
2016
- 2016-07-15 JP JP2018501976A patent/JP2018524373A/ja active Pending
- 2016-07-15 EP EP16823604.0A patent/EP3322735A4/en not_active Withdrawn
- 2016-07-15 CN CN201680053451.9A patent/CN108137706A/zh active Pending
- 2016-07-15 US US15/741,984 patent/US11147886B2/en not_active Expired - Fee Related
- 2016-07-15 WO PCT/CA2016/050839 patent/WO2017008169A1/en not_active Ceased
- 2016-07-15 CA CA2991799A patent/CA2991799A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7592660B2 (ja) | 改善された内部移行特性を有する多重特異性抗原結合分子 | |
| US20230105802A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| TWI593707B (zh) | Ｃｄ３３抗體類及彼等於治療癌症之用途 | |
| KR102514317B1 (ko) | 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법 | |
| DK3102606T3 (en) | ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES | |
| US20230235071A1 (en) | Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer | |
| CN107735105B (zh) | 抗ntb-a抗体和相关组合物以及方法 | |
| WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
| US11497769B2 (en) | Anti-CD19 antibodies | |
| CN108137706A (zh) | 药物缀合的双特异性抗原结合构建体 | |
| JP2024521667A (ja) | 抗－ｃｄ２０５抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬 | |
| AU2024304014A1 (en) | Anti-cd5 antibodies and their uses | |
| WO2026100671A1 (ja) | 抗ｇｐｒｃ５ａ抗体及びその使用 | |
| WO2026060187A1 (en) | Multispecific antibody-drug conjugates (adc) targeting cdh17-expressing tumors and method of making and using thereof |